306 related articles for article (PubMed ID: 20580309)
1. Acute hepatitis B infection associated with drug-resistant hepatitis B virus.
Xu Z; Liu Y; Xu T; Chen L; Si L; Wang Y; Ren X; Zhong Y; Zhao J; Xu D
J Clin Virol; 2010 Aug; 48(4):270-4. PubMed ID: 20580309
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and chronicity of acute hepatitis B induced by lamivudine-resistant strains.
Luo Q; Zhong Y; Yang Y; Xiong Q; Hu Z; Lu W; Huang P; Zhang N
J Med Virol; 2012 Oct; 84(10):1558-61. PubMed ID: 22930503
[TBL] [Abstract][Full Text] [Related]
3. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
4. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
[TBL] [Abstract][Full Text] [Related]
5. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B.
Coppola N; Tonziello G; Colombatto P; Pisaturo M; Messina V; Moriconi F; Alessio L; Sagnelli C; Cavallone D; Brunetto M; Sagnelli E
J Infect; 2013 Oct; 67(4):322-8. PubMed ID: 23796869
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
7. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
Neumann-Fraune M; Beggel B; Pfister H; Kaiser R; Verheyen J
J Med Virol; 2013 May; 85(5):775-9. PubMed ID: 23408582
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B.
Su F; Dai J; Yang S; Jiang X; Cui X; Ning H; Li J; Huang M
J Med Virol; 2015 Sep; 87(9):1527-31. PubMed ID: 26032700
[TBL] [Abstract][Full Text] [Related]
9. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
[TBL] [Abstract][Full Text] [Related]
10. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
[TBL] [Abstract][Full Text] [Related]
11. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?
Lee GH; Aung MO; Dan YY; Lee YM; Mak B; Low HC; Lim K; Thwin MA; Tan PS; Lim SG
J Med Virol; 2013 Jan; 85(1):26-33. PubMed ID: 23023992
[TBL] [Abstract][Full Text] [Related]
12. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
Suzuki F; Kumada H; Nakamura H
J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
[TBL] [Abstract][Full Text] [Related]
13. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
Kim SS; Cho SW; Kim SO; Hong SP; Cheong JY
J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
[TBL] [Abstract][Full Text] [Related]
14. Detection of lamivudine- or adefovir-resistant hepatitis B virus mutations by a liquid array.
Liu H; Mao R; Fan L; Xia J; Li Y; Yin Y; Li X; Zhao X; Guo H; Zhu H; Zhang Y; Kang Y; Zhang J
J Virol Methods; 2011 Jul; 175(1):1-6. PubMed ID: 21513743
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
[TBL] [Abstract][Full Text] [Related]
17. Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay.
Tadokoro K; Suzuki F; Kobayashi M; Yamaguchi T; Nagano M; Egashira T; Kumada H
J Virol Methods; 2011 Jan; 171(1):67-73. PubMed ID: 20950650
[TBL] [Abstract][Full Text] [Related]
18. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
19. Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs.
Salpini R; Svicher V; Cento V; Gori C; Bertoli A; Scopelliti F; Micheli V; Cappiello T; Spanò A; Rizzardini G; De Sanctis GM; Sarrecchia C; Angelico M; Perno CF
Antiviral Res; 2011 Nov; 92(2):382-5. PubMed ID: 21920388
[TBL] [Abstract][Full Text] [Related]
20. Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in Lamivudine-resistant chronic hepatitis B patients.
Song BC; Cui XJ; Shin JW; Park NH; Cho YK; Song HJ; Hyun S; Jeong SU; Choi EK; Kim HU
Intervirology; 2010; 53(4):203-10. PubMed ID: 20332649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
